Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
https://doi.org/10.21518/2079-701X-2019-12-128-131
Abstract
One of the goals of psoriasis therapy is to achieve sustainable remission. Currently, genetically engineered biological drugs are most effective in the treatment of psoriasis. However, there is a certain proportion of patients with insufficient efficiency of genetic engineering biological therapy. One of the reasons for reducing the therapeutic response in patients with psoriasis may be the presence of metabolic syndrome.
Objective: to study the therapeutic efficacy of ustekinumab in patients with psoriasis with metabolic syndrome.
Materials and methods: 52 patients with plaque psoriasis receiving ustekinumab therapy were observed: 25/52 (48.0%) patients with metabolic syndrome, 27/52 (52.0%) - without metabolic syndrome. The proportion of patients who reached PASI75 by the 12th week among patients with psoriasis with and without metabolic syndrome was 17/25 (68.0%) and 23/27 (85.2%) (p>0.05), respectively; 24th week - 15/25 (60.0%) and 25/27 (92.6%) (p<0.05), respectively; 48th week-14/25 (56.0%) and 24/27 (88.9%) (p<0.05).
Conclusion: therapeutic efficacy of ustekinumab is higher in patients with psoriasis without metabolic syndrome than in patients with metabolic syndrome.
About the Authors
I. V. Rychkova
State Budgetary Healthcare Institution of the Republic of Crimea Clinical Dermatovenerologic Dispensary
Russian Federation
Russian Federation
Rychkova Irina Vladimirovna - Dermato-venerologist, Clinical Diagnostic Department.
295006, Simferopol, Bratiev Spendiarovykh Per., 6; tel. +7 (978) 791-31-59
O. A. Prytulo
Georgievsky Medical Academy, Federal State Autonomous Educational Institution of Higher Education Vernadsky Crimean Federal University
Russian Federation
Russian Federation
Prytulo Olga Alexandrovna - Head of Chair for Dermatology and Venereology with Cosmetology Module.
294006, Simferopol, Bulvar Lenina, 5/7; tel. +7 (978) 713-39-79
References
1. Luan L., Han S., Wang H., Liu X. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-a treatment in psoriasis. Int Immunopharmacol. 2015;29:278-284.
2. Nikolashina O.E., Bakulev A.L. On the relationship of innate and adaptive immunity in psoriasis. Saratov journal of medical scientific research. 2015;11(3):421-423. (In Russ.)
3. Khairutdinov V.R., Belousova I.E., Males A.V. Immune pathogenesis of psoriasis. Bulletin of dermatology and venereology. 2016;(4):20-26. (In Russ.)
4. Dovzhansky S.I., Pinson I.Ya. Genetic and immune factors in the pathogenesis of psoriasis. Grown. Journ. coin. and veneric. diseases. 2006;(1):14-19. (In Russ.)
5. Frieder J., Ryan C. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2016;151:678-693.
6. Machado-Pinto J. et al. Psoriasis: new comorbidities. An Bras Dermatol. 2016;91(1):8-14.
7. Abdellatif A.M., Shishov T.A. Metabolic syndrome and its influence on cardiovascular complications in patients with acute coronary syndrome. Modern problems of science and education. 2015;1-1:1346. (In Russ.)
8. Takeshita J. et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377-390.
9. Renato S., Daniela A., Renata N. Metabolic syndrome, C-reactive protein and cardiovascular risk in psoriasis patients: a cross-sectional study. An. Bras. Derma. 2018;93(2):222-228.
10. Rosete-Pidal E.A., Kruglova L.S., Ponich E.S. et al. Therapy of patients with psoriasis with concomitant metabolic syndrome with biological therapy drugs: predictors of effectiveness and potential risks. Occupational medicine and industrial ecology. 2017;(8):33-38. (In Russ.)
11. Prytulo O.A., Kaud Diya. Clinical and biochemical features of the course of psoriatic disease associated with metabolic syndrome. Tauride medical and biological Bulletin. 2012;15(4):170-174. (In Russ.)
12. Mantovani A., Gisondi P., Lonardo A., Targher G. Relationship between nonalcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci. 2016;17:217.
13. Wolk K., Sabat R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17:305-317.
14. Chau Yee N.G. et al. Metabolic parameters in psoriatic patients treated with interleu-kin-12/23 blockade (ustekinumab). Journal of Dermatology. 2017:1-5.
15. Stefanadi E., Dimitrakakis G., Challoumas D., Punjabi N., Dimitrakaki I., Punjabi S., Christodoulos I. Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients. Diabetology & Metabolic Syndrome. 2018;10:9.
16. Strober et al. J Am Acad Dermatol. 2016;74(5):851-860.
Review
For citations:
Rychkova IV, Prytulo OA. Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders. Meditsinskiy sovet = Medical Council. 2019;(12):128-131. (In Russ.) https://doi.org/10.21518/2079-701X-2019-12-128-131
Views:
840
Email this article 